5 completed, 2 terminated, 2 unknown. 9 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 2, Unknown 2 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Central Retinal Vein Occlusion: new trials by email Literature Review of Central Retinal Vein Occlusion trials Research Report on Central Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) 601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-27 | 2025-06-27 |
| Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy - Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | The Emmes Company, LLC | 16 | 2019-10-22 | 2024-12-02 |
| Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Hyperbaric chamber treatment - Central Retinal Vein Occlusion | Phase 2 | Unknown | Assaf-Harofeh Medical Center | 20 | 2015-03-01 | 2015-04-01 |
| Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Intravitreal Aflibercept Injection - Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy | Phase 1 / Phase 2 | Completed | Ophthalmic Consultants of Boston | 24 | 2012-11-01 | 2015-05-22 |
| Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab ranibizumab 0.5mg, ranibizumab 1.0mg - Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | Hanscom, Thomas, M.D. | 14 | 2011-11-01 | 2015-04-29 |
| Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) Bevasizumab, Triamcinolone Acetonide - Central Retinal Vein Occlusion | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 2010-01-01 | 2010-08-10 | |
| Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions nicotinic acid - Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion | Phase 2 / Phase 3 | Terminated | Palo Alto Medical Foundation | 36 | 2007-02-01 | 2019-11-13 |
| The ROVO Study: Radial Optic Neurotomy for CVO Intravitreal Triamcinolone, Radial Optic Neurotomy, Placebo - Sham Intravitreal Injection - Central Retinal Vein Occlusion | Phase 2 / Phase 3 | Completed | Rudolf Foundation Clinic | 2005-04-01 | 2009-10-30 | |
| Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). anecortave acetate - Severe Diabetic Retinopathy, Central Retinal Vein Occlusion | Phase 2 | Terminated | Manhattan Eye, Ear & Throat Hospital | 2002-03-01 | 2007-05-07 |
Retinal Vein Occlusion (9) · Communicable Diseases (1) · Diabetic Retinopathy (1) · Eye Diseases (1) · Macular Edema (1) · Retinal Diseases (1)
Cardiovascular Diseases (9) · Embolism and Thrombosis (9) · Thrombosis (9) · Vascular Diseases (9) · Venous Thrombosis (9) · Eye Diseases (8) · Retinal Diseases (8) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Disease Attributes (1) · Endocrine System Diseases (1) · Infections (1) · Macular Degeneration (1) · Pathologic Processes (1)
Ranibizumab (2) · Niacin (1) · Triamcinolone Acetonide (1) · anecortave acetate (1)
Assaf-Harofeh Medical Center (1) · Hanscom, Thomas, M.D. (1) · Manhattan Eye, Ear & Throat Hospital (1) · Ophthalmic Consultants of Boston (1) · Palo Alto Medical Foundation (1) · Rudolf Foundation Clinic (1) · Shahid Beheshti University of Medical Sciences (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · The Emmes Company, LLC (1)
United States (5) · Austria (1) · China (1) · Iran (1) · Israel (1)
Jeffrey S Heier, MD (1) · Lawrence A. Yannuzzi, MD (1) · Michael Gaynon, MD (1) · Susanna S Park, MD, PhD (1) · Susanne Binder, M.D. (1) · Thomas O'Hearn, MD (1)
1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1)